Exactech stock upgraded to “strong buy” rating: 5 things to know

Zacks upgraded Exactech from a “sell” rating to a “strong buy” rating, according to a Dakota Financial News report.

Advertisement

Here are five things to know:

 

1. Zacks presently has a $21 price target on Exactech’s stock.

 

2. Exactech has a one-year low of $16.11 and a one-year high of $26.20.

 

3. The stock’s 50 day moving average is $17.63 and its 200-day moving average is $18.77.

 

4. The stock has a market cap of $259.46 million.

 

5. On average, Exactech has an average rating of “buy” and a consensus target price of $25.

 

More articles on devices:
Researchers make new discovery on bone fracture healing: 5 key notes
SeaSpine signs 3-year, $30M credit facility: 5 key notes
Stryker director sells 18k shares, following Smith & Nephew acquisition rumors: 7 points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.